MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025

Core Viewpoint - MediciNova, Inc. is actively engaging with investors at the upcoming DBC Conference, highlighting its focus on innovative treatments for serious diseases with unmet medical needs, particularly in neurologic and metabologic disorders [1][2]. Company Overview - MediciNova, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for serious diseases, primarily targeting the U.S. market [2]. - The company's leading programs include MN-166 (ibudilast) for various neurological disorders and MN-001 (tipelukast) for fibrotic and metabolic disorders [2]. - Current therapeutic targets for MN-166 include amyotrophic lateral sclerosis (ALS), progressive multiple sclerosis (MS), chemotherapy-induced peripheral neuropathy, and Long COVID, among others [2]. - MN-001 is being developed for conditions such as nonalcoholic fatty liver disease (NAFLD) and hypertriglyceridemia [2]. - The company plans to advance its pipeline through a mix of investigator-sponsored clinical trials, government grants, and strategic alliances [2]. Upcoming Events - CEO Yuichi Iwaki and CBO David H. Crean will participate in investor meetings at the DBC Conference on May 14, 2025, in New York City [1]. - The conference aims to connect public and private executives with institutional investors and corporate clients across various sectors, including Healthcare & Life Sciences [1].